Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems

Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.

Drawing bullseye
A new guidance takes aim at the data integrity problems that have plagued industry in recent years • Source: Shutterstock

A new US Food and Drug Administration guidance takes aim at heading off a high-profile problem that has troubled the generic drug industry in recent years – fraud and other data integrity issues with bioavailability and bioequivalence studies.

Recommendations in the draft guidance, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,” are aimed at addressing the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By 

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

US Federal Circuit Clears Path for MSN to Market Entresto Generic

 
• By 

Novartis has failed to secure a court order to stop MSN from launching a generic Entresto, and has also seen an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.

Regulatory Recap: FDA Starts ‘Radical Transparency’ Era After Publishing Over 200 CRLs

 

Generics Bulletin reviews global regulatory developments across the world.

Industry Welcomes Support From UK Life Sciences Plan

 
• By 

A new life sciences strategy unveiled by the UK government has won plaudits from the off-patent industry for its inclusion of measures specifically geared towards generics and biosimilars – especially a £1bn savings target linked to biosimilar uptake.

More from Products